Fig. 2

Validation of radiosensitizing targets to TRT. a Reduced proliferation of A431/CCKBR cells treated with kinase inhibitor library in combination with [¹⁷⁷Lu]Lu-PP-F11N, shown as log2 [ratio: combinatory treatment/[¹⁷⁷Lu]Lu-PP-F11N monotherapy]. Red dots represent inhibitors, which significantly increased therapeutic response to [¹¹⁷Lu]Lu-PP-F11N (P < 0.05). b Cell proliferation 48 h after treatment with 10 µM STS, BML-265 and TYRPHOSTIN AG 1478 alone or in combination with 5 MBq per ml of [¹⁷⁷Lu]Lu-PP-F11N. c A431/CCKBR cell proliferation was analyzed 72 h after treatment with 20 µM cilengitide (CGT) and/or 5 and 10 MBq per ml of [¹⁷⁷Lu]Lu-PP-F11N, as indicated. Results were assayed in triplicate and proliferation in control untreated cells was set to 1. Data represent means ± SD. d Experimental design of in vivo study: After implantation of A431/CCKBR cells into nude mice, 10 doses of cilengitide (CGT) or erlotinib were administrated alone or in combination with 60 kBq [¹⁷⁷Lu]Lu-PP-F11N, as indicated. e Tumor growth curves of control and treated groups. Data represent mean ± SD. f Survival rates presented as Kaplan–Meier curves of control and treated mice. g Extended median survival in treated groups as compared to control mice. *P < 0.05, **P < 0.01, ***P < 0.001